Wolverhampton Wanderers have announced that Nigeria International, Carl Ikeme has been diagnosed with acute leukaemia.
The 31-year-old goalkeeper returned some abnormal blood tests during his pre-season testing, and further medical investigation has revealed he is suffering from leukaemia.
Carl will now start an immediate course of chemotherapy as he begins a lengthy battle against the disease the said in a statement issued on Thursday.
All of our thoughts are with Carl and, as a club, we will be right behind him every step of the way throughout his fight.
— Wolves (@Wolves) July 6, 2017
“It would be an understatement to say that everyone at Wolves has been shocked and saddened to hear the news of Carl’s diagnosis,” said Wolves’ Managing Director Laurie Dalrymple.
“That relates to both players and staff as Carl has been at the club for a very long time and remains such an integral personality within the group.
“At the same time, we all know what a fighter and a competitor Carl is, and I have no doubt that he will take all of those attributes into this battle.
“Similarly, its goes without saying that Carl and his family will receive the full love and support that we at Wolves can provide – we are all with him every single step of the way towards a full recovery.
“There are going to be some very tough times ahead, but he will receive the best possible care, aided and supported by our own club doctor and medical team, as he embarks on the lengthy process of treatment.
“We are speaking to Carl regularly, and sending him our very best wishes as he comes to terms with this news and starts his recovery.”
The club also said, “Carl and his family would request that their privacy be respected at this time, and any updates on his progress will be provided through the club.”
This news also mean the goalkeeper’s future with the national team is no longer certain and he may not return.
If you use the quotes from this content, you legally agree to give www.brila.net the News credit as the source and a backlink to our story. Copyright 2020 Brila Media.